CORC

在结果中检索

CORC

浏览/检索结果: 共16条，第1-10条 帮助

限定条件    
已选(0)清除 条数/页：   排序方式：
Phase III trial of chidamide, a subtype-selective histone deacetylase (HDAC) inhibitor, in combination with exemestane in patients with hormone receptor-positive advanced breast cancer 期刊论文
ANNALS OF ONCOLOGY, 2018, 卷号: 29
作者:  Jiang, Z.;  Li, W.;  Hu, X.;  Zhang, Q.;  Sun, T.
收藏  |  浏览/下载：2/0  |  提交时间：2019/12/05
Marital Status and Survival of Patients with Hormone Receptor-Positive Male Breast Cancer: A Surveillance, Epidemiology, and End Results (SEER) Population-Based Study 期刊论文
MEDICAL SCIENCE MONITOR, 2018, 卷号: 24
作者:  Liu, Lei;  Chi, Ya-Yun;  Wang, An-An;  Luo, Yonghui
收藏  |  浏览/下载：2/0  |  提交时间：2019/12/05
Impact of hormone receptor status and distant recurrence-free interval on survival benefits from trastuzumab in HER2-positive metastatic breast cancer (vol 7, 1134, 2017) 期刊论文
SCIENTIFIC REPORTS, 2018, 卷号: 8
作者:  Yang, Hai-Yuan;  Ma, Ding;  Liu, Yi-Rong;  Hu, Xin;  Zhang, Jian
收藏  |  浏览/下载：2/0  |  提交时间：2019/12/05
Health-related quality of life from the FALCON phase III randomised trial of fulvestrant 500 mg versus anastrozole for hormone receptor-positive advanced breast cancer 期刊论文
EUROPEAN JOURNAL OF CANCER, 2018, 卷号: 94
作者:  Robertson, John F. R.;  Cheung, Kwok-Leung;  Noguchi, Shinzaburo;  Shao, Zhimin;  Degboe, Arnold
收藏  |  浏览/下载：8/0  |  提交时间：2019/12/05
Progression-free survival results in postmenopausal Asian women: subgroup analysis from a phase III randomized trial of fulvestrant 500 mg vs anastrozole 1 mg for hormone receptor-positive advanced breast cancer (FALCON) 期刊论文
BREAST CANCER, 2018, 卷号: 25, 期号: 3
作者:  Noguchi, Shinzaburo;  Ellis, Matthew J.;  Robertson, John F. R.;  Thirlwell, Jackie;  Fazal, Mehdi
收藏  |  浏览/下载：1/0  |  提交时间：2019/12/05
Phase III trial of chidamide, a subtype-selective histone deacetylase (HDAC) inhibitor, in combination with exemestane in patients with hormone receptor-positive advanced breast cancer 会议论文
作者:  Jiang, Z.;  Li, W.;  Hu, X.;  Zhang, Q.;  Sun, T.
收藏  |  浏览/下载：6/0  |  提交时间：2019/12/05
The clinical benefit of epidermal growth factor receptor and human epidermal growth factor receptor 2 targeted agents adding to endocrine therapy in hormone receptor-positive breast cancer 期刊论文
JOURNAL OF CANCER RESEARCH AND THERAPEUTICS, 2018, 卷号: 14
作者:  Li, Huan;  Zhai, Qing;  Yu, Bo
收藏  |  浏览/下载：9/0  |  提交时间：2019/12/05
Sequential versus simultaneous use of chemotherapy and gonadotropin-releasing hormone agonist (GnRHa) among estrogen receptor (ER)-positive premenopausal breast cancer patients: effects on ovarian function, disease-free survival, and overall survival 期刊论文
BREAST CANCER RESEARCH AND TREATMENT, 2018, 卷号: 168, 期号: 3
作者:  Zhang, Ying;  Ji, Yajie;  Li, Jianwei;  Lei, Li;  Wu, Siyu
收藏  |  浏览/下载：15/0  |  提交时间：2019/12/05
Sequential versus simultaneous use of chemotherapy and gonadotropin-releasing hormone agonist (GnRHa) among estrogen receptor (ER)-positive premenopausal breast cancer patients: effects on ovarian function, disease-free survival, and overall survival 期刊论文
BREAST CANCER RESEARCH AND TREATMENT, 2018, 卷号: 168, 期号: 3
作者:  Shao, Zhimin;  Zhang, Ying;  Ji, Yajie;  Li, Jianwei;  Lei, Li
收藏  |  浏览/下载：4/0  |  提交时间：2019/12/05
Sequential versus simultaneous use of chemotherapy and gonadotropin-releasing hormone agonist (GnRHa) among estrogen receptor (ER)-positive premenopausal breast cancer patients: effects on ovarian function, disease-free survival, and overall survival 期刊论文
Breast cancer research and treatment, 2018, 卷号: 168, 页码: 679-686
作者:  Zhang Ying[1];  Ji Yajie[2];  Li Jianwei[3];  Lei Li[4];  Wu Siyu[5]
收藏  |  浏览/下载：5/0  |  提交时间：2019/04/24

©版权所有 ©2017 CSpace - Powered by CSpace